Caplin Point Laboratories Limited (CAPLIPOINT.NS)
INR 1844.6
(-4.77%)
INR 1844.6
(-4.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.97 Billion INR | 23.09% |
| 2022 | 21.91 Billion INR | 26.21% |
| 2021 | 17.36 Billion INR | 27.33% |
| 2020 | 13.63 Billion INR | 21.13% |
| 2019 | 11.25 Billion INR | 51.61% |
| 2018 | 7.42 Billion INR | 48.37% |
| 2017 | 5 Billion INR | 39.66% |
| 2016 | 3.58 Billion INR | 34.14% |
| 2015 | 2.67 Billion INR | 16.74% |
| 2014 | 2.28 Billion INR | 27.19% |
| 2013 | 1.79 Billion INR | 33.36% |
| 2012 | 1.34 Billion INR | 25.94% |
| 2011 | 1.07 Billion INR | 44.55% |
| 2010 | 741.04 Million INR | 22.48% |
| 2009 | 605.04 Million INR | -1.34% |
| 2008 | 613.24 Million INR | 9.83% |
| 2007 | 558.36 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 26.97 Billion INR | 0.0% |
| 2023 Q2 | 24.12 Billion INR | 0.0% |
| 2023 FY | 26.97 Billion INR | 23.09% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 20.21 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 21.91 Billion INR | 0.0% |
| 2022 FY | 21.91 Billion INR | 26.21% |
| 2021 Q2 | 15.65 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 17.36 Billion INR | 0.0% |
| 2021 FY | 17.36 Billion INR | 27.33% |
| 2020 FY | 13.63 Billion INR | 21.13% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 12.74 Billion INR | 0.0% |
| 2020 Q4 | 13.63 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 9.26 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 11.25 Billion INR | 0.0% |
| 2019 FY | 11.25 Billion INR | 51.61% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 7.42 Billion INR | 0.0% |
| 2018 FY | 7.42 Billion INR | 48.37% |
| 2018 Q2 | 5.89 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 5 Billion INR | 0.0% |
| 2017 FY | 5 Billion INR | 39.66% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 4.08 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 3.58 Billion INR | 34.14% |
| 2016 Q4 | 3.58 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 2.87 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 FY | 2.67 Billion INR | 16.74% |
| 2015 Q1 | 2.28 Billion INR | 0.0% |
| 2015 Q2 | 2.47 Billion INR | 8.08% |
| 2015 Q3 | 2.47 Billion INR | 0.0% |
| 2015 Q4 | 2.67 Billion INR | 8.01% |
| 2014 Q4 | - INR | -100.0% |
| 2014 FY | 2.28 Billion INR | 27.19% |
| 2014 Q1 | 1.79 Billion INR | 0.0% |
| 2014 Q2 | - INR | -100.0% |
| 2014 Q3 | 2.14 Billion INR | 0.0% |
| 2013 Q1 | 1.34 Billion INR | 0.0% |
| 2013 Q4 | - INR | -100.0% |
| 2013 FY | 1.79 Billion INR | 33.36% |
| 2013 Q3 | 1.64 Billion INR | 0.0% |
| 2013 Q2 | - INR | -100.0% |
| 2012 Q3 | 1.14 Billion INR | 0.0% |
| 2012 Q1 | 1.07 Billion INR | 0.0% |
| 2012 FY | 1.34 Billion INR | 25.94% |
| 2012 Q4 | - INR | -100.0% |
| 2011 FY | 1.07 Billion INR | 44.55% |
| 2010 FY | 741.04 Million INR | 22.48% |
| 2009 FY | 605.04 Million INR | -1.34% |
| 2008 FY | 613.24 Million INR | 9.83% |
| 2007 FY | 558.36 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 58.151% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -1726.483% |
| FDC Limited | 24.68 Billion INR | -9.29% |
| Gufic Biosciences Limited | 10.92 Billion INR | -146.89% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 76.643% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -23.109% |
| Orchid Pharma Limited | 15.53 Billion INR | -73.591% |
| Alkem Laboratories Limited | 155.74 Billion INR | 82.681% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -252.54% |
| Brooks Laboratories Limited | 904.45 Million INR | -2882.33% |
| Eris Lifesciences Limited | 70.48 Billion INR | 61.733% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 5.369% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | -14.948% |
| Innova Captab Limited | 13.2 Billion INR | -104.211% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -1142.586% |
| Wanbury Limited | 3.43 Billion INR | -685.279% |
| Lupin Limited | 239.97 Billion INR | 88.76% |
| Aarti Drugs Limited | 24.32 Billion INR | -10.896% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -4.465% |
| Albert David Limited | 4.97 Billion INR | -441.652% |
| Alembic Limited | 23.28 Billion INR | -15.829% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -5629.026% |
| Hester Biosciences Limited | 6.62 Billion INR | -307.246% |
| Hikal Limited | 24.87 Billion INR | -8.453% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -131.514% |
| Ind-Swift Limited | 6.54 Billion INR | -312.146% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -20.183% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -1023.62% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -285.18% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -708.993% |
| Medico Remedies Limited | 961.95 Million INR | -2704.066% |
| Morepen Laboratories Limited | 12.93 Billion INR | -108.581% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -239.566% |
| RPG Life Sciences Limited | 5.12 Billion INR | -425.938% |
| Sigachi Industries Limited | 6.94 Billion INR | -288.584% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 96.844% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -19.666% |
| Themis Medicare Limited | 5.66 Billion INR | -376.218% |
| Unichem Laboratories Limited | 31.69 Billion INR | 14.892% |
| Vaishali Pharma Limited | 799.55 Million INR | -3273.593% |
| Venus Remedies Limited | 6.26 Billion INR | -330.321% |
| Windlas Biotech Limited | 6.26 Billion INR | -330.75% |
| ZIM Laboratories Limited | 4.46 Billion INR | -503.681% |
| Sakar Healthcare Limited | 3.88 Billion INR | -594.022% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 94.015% |
| Divi's Laboratories Limited | 154.7 Billion INR | 82.564% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -150.214% |
| Mankind Pharma Limited | 119.63 Billion INR | 77.453% |
| Sequent Scientific Limited | 15.4 Billion INR | -75.111% |
| Laurus Labs Limited | 83.87 Billion INR | 67.839% |
| Neuland Laboratories Limited | 18.32 Billion INR | -47.192% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 32.466% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 81.214% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 90.788% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -635.24% |
| Wockhardt Limited | 76.49 Billion INR | 64.736% |
| Bal Pharma Limited | 3.2 Billion INR | -741.908% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 93.039% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -122.214% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -2554.612% |
| Shilpa Medicare Limited | 30.93 Billion INR | 12.797% |
| Valiant Laboratories Limited | 3.42 Billion INR | -687.126% |
| Ajanta Pharma Limited | 46.38 Billion INR | 41.847% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -784.41% |
| Granules India Limited | 55.2 Billion INR | 51.143% |
| Medicamen Biotech Limited | 2.94 Billion INR | -815.849% |
| Ipca Laboratories Limited | 111.01 Billion INR | 75.702% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -566.573% |
| Piramal Enterprises Limited | 826.05 Billion INR | 96.735% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 82.09% |
| NATCO Pharma Limited | 69.06 Billion INR | 60.943% |
| Suven Life Sciences Limited | 2.84 Billion INR | -846.772% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -1413.896% |
| Strides Pharma Science Limited | 58.39 Billion INR | 53.81% |
| Indoco Remedies Limited | 21.44 Billion INR | -25.768% |
| Alpa Laboratories Limited | 1.82 Billion INR | -1377.031% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -1687.899% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -423.722% |